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Abstract
Background Bartter patients may be hypercalciuric. Addition-
al abnormalities in the metabolism of calcium, phosphate, and
calciotropic hormones have occasionally been reported.
Methods The metabolism of calcium, phosphate, and
calciotropic hormones was investigated in 15 patients with
Bartter syndrome and 15 healthy subjects.
Results Compared to the controls, Bartter patients had signif-
icantly reduced plasma phosphate {mean [interquartile
range]:1.29 [1.16–1.46] vs. 1.61 [1.54–1.67] mmol/L} and
maximal tubular phosphate reabsorption (1.16 [1.00–1.35]
vs. 1.41 [1.37–1.47] mmol/L) and significantly increased
parathyroid hormone (PTH) level (6.1 [4.5–7.7] vs. 2.8
[2.2–4.4] pmol/L). However, patients and controls did not
differ in blood calcium, 25-hydroxyvitamin D, alkaline phos-
phatase, and osteocalcin levels. In patients, an inverse corre-
lation (P<0.05) was noted between total plasma calcium or
glomerular filtration rate and PTH concentration. A positive
correlation was also noted between PTH and osteocalcin
concentrations (P<0.005), as well as between chloriduria or
natriuria and phosphaturia (P<0.001). No correlation was
noted between calciuria and PTH concentration or between
urinary or circulating phosphate and PTH.
Conclusions The results of this study demonstrate a tendency
towards renal phosphate wasting and elevated circulating PTH
levels in Bartter patients.
Keywords Bartter syndrome . Calcium .
Hypophosphatemia .Maximal tubular reabsorption of
phosphate . Parathyroid hormone
Introduction
Bartter syndrome is a group of very similar recessive
tubulopathies with a unifying pathophysiology consisting of
postproximal salt loss [1]. Affected patients present with
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normal or low blood pressure, hypokalemia, hyperreninemia,
and a tendency towards nephrocalcinosis and hypercalciuria in
the neonatal variant [1]. Further abnormalities in the metabo-
lism of calcium, inorganic phosphate, and calciotropic hor-
mones have sometimes been noted in these disorders, although
data characterizing the levels of classic calciotropic hormones
during the stable phases of the condition are sparse [2, 3].
Here we present the results of our study in which we
investigated the metabolism of calcium, inorganic phosphate,
and classic calciotropic hormones in patients affected with
Bartter syndrome.
Patients and methods
Participants eligible for entry into the study were all Bartter
patients on regular follow-up at the renal unit of the Division of
Pediatrics, San Leopoldo Mandic Hospital, Merate (Italy). Fif-
teen patients from 14 different families (8 females and 7 males,
median age 7.3 years, age range 3.2–18) who presented for a
scheduled visit between September and November 2012 were
ultimately enrolled in the study. These patients had a history of
polyhydramnios (N=13), premature birth (N=13), or ultrasound
findings consistent with nephrocalcinosis (N=13) (Table 1). A
control group of 15 healthy subjects (8 females and 7 males
median age 11 years, age range 6.9–18 years) was also studied.
The study design was approved by the Human Subjects Re-
search Committee of Merate-Lecco Hospital.
The diagnosis of Bartter syndrome was based on the pres-
ence of normal or low blood pressure, hypokalemia, inappro-
priately high urinary excretion of chloride, and hyperreninemia.
A molecular evaluation of the SLC12A1, KCNJ1, CLCNKB,
and BSND genes had been performed on the 15 patients,
according to standard procedure [4, 5]. The Bartter patients,
who did not discontinue their respective medication with po-
tassium chloride (N=15), the inhibitor of prostaglandin synthe-
sis indomethacin (N=14), and the potassium-sparing diuretic
spironolactone (N=3), and the control subjects attended the
outpatient clinic after overnight fasting and received a tap water
load of 400 mL [6]. After voiding the bladder, an approximate-
ly 2-h urine specimen was collected and a mid-point blood
sample was collected [6]. Creatinine, sodium, chloride, potas-
sium, total calcium and magnesium, and inorganic phosphate
were assessed in both the blood and urine; urea, bicarbonate,
albumin, 25-hydroxyvitamin D, alkaline phosphatase, intact
parathyroid hormone (PTH), and osteocalcin were assessed in
the blood only. Creatinine, urea, sodium, bicarbonate, chloride,
potassium, albumin, total calcium and magnesium, and inor-
ganic phosphate were measured on an automated auto-analyzer
using colorimetric assays or ion-selective electrodes. Intact
PTH was measured by a two-site radioimmunometric assay,
25-hydroxyvitamin D was measured using a competitive
Table 1 Mutations and main clinical prenatal and neonatal data in 15 patients with Bartter syndromes
Patient numbera Geneb Nucleotide changesc Polyhydramnios Gestational age (weeks) Nephrocalcinosis
1 SLC12A1 c.[730insG]; [1432G>A] Yes 30 Yes
2 c.[903_904delC]; [1493C>T] Yes 36 Yes
3 c.[572 T>A]; [1493C>T] Yes 28 Yes
4 c.[1567delT]; [?] Yes 35 Yes
5 c.[366G>A]; [1973 G>A] Yes 34 Yes
6 c.[570 T>A]; [630 T>C] Yes 31 Yes
7d KCNJ1 c.[629C>T]; [629C>T] Yes 32 Yes
8d c.[629C>T]; [629C>T] Yes 37 Yes
9 CLCNKB c.[850_855 dupT]; [1-?_2064+?del] No 40 Yes
10 c.[725C>A]; [1 ?_2064+?del] Yes 39 No
11 c.[206 C>A]; [480 T>A] No 40 No
12 BSND c.[3G>A]; [3G>A] Yes 39 Yes
13 Not detected Yes 39 Yes
14 Yes 33 Yes
15 Yes 38 Yes
a Patients 1–8 and patients 14 and 15 were classified clinically as loop disorder Bartter syndrome; patients 9–11 and 13 were classified as distal
convoluted tubule disorder Bartter syndrome; patient 12 was classified as combined disorder Bartter syndrome
bMutations of the SLC12A1, KCNJ1, CLCNKB, and BSND genes were detected in 12 of the 15 patients. GenBank accession numbers as reference
sequences: SLC12A3=NM_000339.2; SLC12A1=NM_000338.2; KCNJ1=NM_000220.3; CLCNKB=NM_000085.4. Nomenclature according to
Human Genomic Variant Society
c Novel mutations are given in bold font
d These patients are first-degree cousins
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protein-binding assay, and osteocalcin was measured by radio-
immunoassay, as previously reported [6].
The glomerular filtration rate (GFR) was estimated from
height measurements and plasma creatinine levels [7]. Stan-
dard equations were used to calculate the fractional urinary
excretion of sodium, chloride, potassium, calcium, magne-
sium, and inorganic phosphate and the maximal tubular reab-
sorption of inorganic phosphate, which is the best means of
defining the renal tubular handling of this ion [8, 9]. Albumin-
corrected plasma calcium was calculated as follows: for every
gram/liter by which plasma albumin exceeds 40 g/L, 0.025 is
subtracted from the total calcium measurement, with the re-
verse procedure for albumin values of <40 g/L. Blood and
urinary levels of sodium, chloride, potassium, and magnesium
are age- and gender-independent [10], but blood levels of
inorganic phosphate and those of its maximal tubular reab-
sorption vary significantly with age and gender [8, 9]. Hence,
the values obtained in our study were also compared with
those given in the literature [8, 9] and expressed as the
standard deviation score (SDS).
Table 2 Laboratory findings in
the 15 patients affected with
Bartter syndrome and in the 15
control subjectsa
Values are presented as the medi-
an with the interquartile range
(IQR) given in square brackets
SDS, Standard deviation score;
NS, not significant; PTH, para-
thyroid hormone
a Patients affected with Bartter
syndrome: N = 15; 8 females, 7
males; median age 7.3 years; age
range 3.2–18.0 years. Control
subjects: N = 15; 7 females, 8
males; median age 11.1 years;
age range 6.9-17.8 years
b Glomerular filtration rate was
≥85 mL/(min.1.73 m2 ) in 14 of
the 15 patients
Laboratory findings Patients with Bartter
syndrome
Control
subjects
Significance
(P value)
Body height (m)
Absolute value 1.17 [1.02–1.50] 1.49 [1.40–1.54] <0.01
SDS −1.6 [-0.9 to −2.3] 0.3 [−0.3 to 0.8] <0.01
Body weight (kg)
Absolute value 19.7 [15.3–37.5] 42.5 [37.0–49.5] <0.03
SDS −1.6 [−1.0 to −2.8] 0.4 [−0.3 to 0.8] <0.01
Marshall–Tanner puberty stage 2 [1–5] 2 [1–5] NS
Plasma creatinine (μmol/L) 53 [35– 66] 55 [50–57] NS
Glomerular filtration rate
[mL/(min.1.73 m2)]
135 [125–144]b 132 [126–138] NS
Plasma urea (mmol/L) 4.3 [4.2–7.2] 5.8 [4.5–6.0] NS
Sodium
Plasma level (mmol/L) 137 [136–138] 136 [135–137] NS
Fractional excretion, 10-2 0.43 [0.27–1.34] 0.50 [0.30–0.61] NS
Plasma bicarbonate (mmol/L) 27 [26–28] 27 [26–28] NS
Chloride
Plasma level (mmol/L) 100 [99–102] 101 [100–102] NS
Fractional excretion, 10-2 1.05 [0.66– 2.10] 0.60 [0.4–0.75] <0.001
Potassium
Plasma level (mmol/L) 3.3 [3.0–3.6] 4.0 [3.9–4.3] <0.001
Fractional excretion, 10-2 13.9 [11.6– 44.9] 5.3 [3.1–9.2] <0.005
Magnesium
Plasma level (mmol/L) 0.90 [0.80–1.00] 0.91 [0.79–0.94] NS
Fractional excretion, 10-2 4.27 [2.70–4.60] 3.20 [2.65–4.08] NS
Calcium
Total plasma level (mmol/L) 2.36 [2.35–2.42] 2.41 [2.38–2.45] NS
Albumin corrected level (mmol/L) 2.37 [2.34–2.44] 2.41 [2.36–2.46] NS
Fractional excretion, 10-2 1.77 [1.17–2.63] 0.81 [0.63–1.11] <0.05
Inorganic phosphate
Plasma level (mmol/L) 1.29 [1.16–1.46] 1.61 [1.54–1.67] <0.01
Plasma level SDS −0.5 [−1.3 to 0.1] 1.0 [0.4–1.3] <0.01
Fractional excretion, 10-2 9.0 [5.8–14.4] 11.4 [10.0–13.0] NS
Maximal tubular reabsorption (mmol/L) 1.16 [1.00–1.35] 1.41 [1.37–1.47] <0.01
Maximal tubular reabsorption SDS −0.7 [−1.6 to 0.3] 0.5 [0.3–1.0] <0.01
Serum 25-hydroxyvitamin D (mmol/L) 48 [35–60] 44 [33–48] NS
Plasma alkaline phosphatase (U/L) 244 [208–304] 256 [194–324] NS
Serum intact PTH (pmol/L) 6.1 [4.5–7.7] 2.8 [2.2–4.4] <0.001
Serum osteocalcin (μg/L) 59.2 [38.1–90.4] 66.4 [48.0–103.0] NS
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Descriptive statistics are presented as the median and in-
terquartile range (25th to 75th percentile and includes half of
the data points). Two-tailed Wilcoxon–Mann–Whitney tests
for independent samples and linear regressions with the rank
correlation coefficient rs were performed for the analysis.
Significance was assumed when P<0.05.
Results
Molecular biology
Genetic analysis revealed mutations in 12 of the 15 patients
enrolled in the study, with three patients having a homozygous
mutation, eight having a compound heterozygous mutation,
and one having a single heterozygous mutation (Table 1). One
of these patients has been previously diagnosed as Bartter
syndrome type IV based on the presence of a sensorineural
hearing loss [11]. Ten mutations had been previously de-
scribed, whereas seven mutations (4 missense and 1 frame-
shift in the SLC12A1 gene and 1 missense and 1 frameshift in
the CLCNKB gene) are novel. All of the new variants were
considered to be pathogenetic—the two frameshift mutations
because they lead to truncated protein synthesis, and the
missense mutations because all are on conserved residues
and were not detected in 100 healthy chromosomes or found
in the Exome Variant Server database. Molecular analysis did
not detect any mutation in three patients.
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Fig. 1 Total plasma calcium and
inorganic phosphate levels,
fractional calcium excretion,
maximal tubular reabsorption of
inorganic phosphate, and serum
intact parathyroid hormone and
25-hydroxyvitamin D levels in 15
Bartter syndrome patients and in
15 control subjects. Differently
colored filled circles denote
patients with mutations affecting
either the SLC12A1 or the KCNJ1
gene (type I–II), patients with
mutations affecting the CLCNK
gene (type III) patients with
mutations affecting the BSND
(Barttin), and patients without any
mutation, as well as the control
subjects. NS Not significant. See
text and Table 2 for a detailed
description of the two study
groups
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Fig. 2 Relationship between maximal tubular reabsorption of inorganic
phosphate and corresponding plasma phosphate level in 15 Bartter syn-
drome patients and 15 control subjects. The results are expressed as
standard deviation score (SDS). Shaded area Reference values obtained
from the literature. Differently colored filled circles denote patients with
mutations affecting either the SLC12A1 or the KCNJ1 gene (type I–II),
patients with mutations affecting the CLCNK gene (type III) patients with
mutations affecting the BSND (Barttin), and patients without any muta-
tion, as well as the control subjects
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Clinical and biochemical data
Growth and laboratory findings are shown in Table 2 and
Fig. 1. Body height, height SDS, weight and weight SDS
were significantly lower in the group of patients affected with
Bartter syndrome than in the control group. Patients affected
with Bartter syndrome and control subjects did not signifi-
cantly differ with respect to puberty stage, plasma creatinine
and urea, estimated GFR, plasma bicarbonate and chloride,
and plasma and urinary sodium and magnesium. As expected,
hypokalemia, hyperkaliuria, hyperchloriduria, and hypercal-
ciuria were noted in Bartter patients. Plasma inorganic phos-
phate level (P<0.01) and maximal tubular phosphate reab-
sorption were significantly reduced (P<0.01) and serum intact
PTH level significantly increased (P<0.01) in Bartter patients
as compared with control subjects. However, patients and
controls did not significantly differ with respect to total calci-
um blood level, serum 25-hydroxyvitamin D, plasma alkaline
phosphatase and serum osteocalcin. PTH level was >10
pmol/L in three patients, with only one of these three patients
having a mildly reduced GFR of 58 mL/(min.1.73 m2).
Figure 2 shows the relationship between the maximal
tubular reabsorption of phosphate and its plasma level
in Bartter patients and healthy controls, which are com-
pared with age- and sex-specific reference values from
the literature [4, 5]. The maximal tubular reabsorption
of phosphate was low in three patients, and circulating
phosphate level was low in one patient.
In Bartter patients we noted a significant inverse correlation
(P<0.05) between total plasma calcium or GFR, taken as the
independent value, and PTH, taken as the dependent value
(Table 3). Finally, a significant positive correlation was noted
between PTH and osteocalcin (P<0.005) and between urinary
chloride or sodium and urinary phosphate (P<0.001).
On the contrary, no significant correlation was noted
between urinary calcium and PTH, between urinary or
circulating phosphate and PTH, and between maximal
tubular reabsorption of phosphate and PTH.
Discussion
The clinical and laboratory characteristics of Bartter syndrome
may be mimicked among others by treatment with loop
diuretics [1]. These natriuretic agents directly increase urinary
phosphate excretion in the presence of a normal extracellular
fluid volume [12]. On the other hand, there is no phosphaturia
in the presence of a contracted extracellular fluid volume, i.e.,
when urinary salt losses are not replaced [12]. Our case–
control study was performed in biochemically and genetically
characterized Bartter patients. In these unselected patients,
who were on long-term management with potassium chloride,
indomethacin and, more rarely, spironolactone, we deter-
mined hypercalciuria, renal phosphate wasting, and elevated
circulating PTH levels.
The molecular biology studies performed in our patients
also disclosed seven previously unreported mutations in either
the SLC12A1 or CLCNKB genes.
To our knowledge, the metabolism of calcium, inorganic
phosphate, and PTH in Bartter patients has only been
Table 3 Significant regressions in 15 patients with Bartter syndrome
Independent value Dependent value Slope Intercept Correlation
coefficient (rs)
Significance (P)
Total calcium level Intact PTH −146.1 414 −0.529 <0.05
Glomerular filtration rate Intact PTH −0.277 98.9 −0.521 <0.05
Intact parathyroid hormone Osteocalcin 0.974 0.439 0.800 <0.005
Fraction chloride excretion Fractional phosphate excretion 2.90 5.76 0.822 <0.001
Fractional sodium excretion Fractional phosphate excretion 7.54 5.24 0.814 <0.001
PTH parathyroid hormone
Table 4 Data on blood calcium, inorganic phosphate, and parathyroid hormone levels and on urinary phosphate excretion in patients affected with
Bartter syndromes
Reference Glomerular filtration rate
[mL/(min.1.73 m2)]
Blood level (mmol/L) Urinary phosphate
excretion
PTH Calcium Phosphate
Leonhardt et al. [2] Reduced Elevated Low Elevated Normal
Rodríguez-Soriano et al. [3] Normal Normal Normal–high Low Not assessed
Present study Normal Elevated Normal Low Elevated
PTH parathyroid hormone
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addressed in our study and in two earlier studies [2, 3],
although the latter two studies did not include a well-defined
pediatric control group (Table 4). The tendency towards ele-
vated PTH levels and hyperphosphatemia noted in German
patients in the study of Leonhardt et al. [2] is likely the
consequence of a mildly reduced GFR. As in our patients, a
tendency towards hypophosphatemia was noted in Span-
ish pediatric patients, reported by Rodríguez-Soriano
et al. [3], with a normal GFR (phosphaturia was not
measured in these patients). However, contrary to our
patients, in the Spanish patients, the PTH level was
normal and the circulating calcium level was slightly
elevated. As in our patients, hypophosphatemia and hy-
perparathyroidism were also noted in an adolescent case
of Bartter syndrome reported 35 years ago [13].
The mechanisms underlying renal phosphate wasting and
hypophosphatemia in Bartter patients remain elusive. Bartter
patients tend to be alkalotic; it is recognized, however, that
metabolic alkalosis, contrary to respiratory alkalosis, does not
noticeably modify phosphate metabolism [14–16]. There is
some phosphate wasting in primary hyperparathyroidism, but
no correlation was noted between urinary or circulating phos-
phate and PTH in our Bartter patients [17]. Prostaglandin
overproduction, a constant finding in Bartter syndrome, might
underlie hyperphosphaturia in our patients [14–16]. This as-
sumption is supported by the observation that circulating
phosphate levels increase in patients with Barter syndromes
who are being treated with inhibitors of prostaglandin synthe-
sis [2]. When we take into account that our Bartter patients
were on treatment with indomethacin, an effective inhibitor of
prostaglandin synthesis, we can assume that factors other than
hyperprostaglandinism mainly account for renal phosphate
wasting. We feel that the mild tendency to renal phosphate
wasting observed in our Bartter patients results from a
phosphaturic effect associated with the renal tubular dysfunc-
tion, which is in part counterbalanced by existing extracellular
fluid volume contraction [12]. This impression is supported by
the significant correlation between urinary chloride or sodium
and urinary phosphate.
There are a number of limitations to our study. First, we
included Bartter patients with both prenatal and classic pre-
sentation. Second, only a few patients (N = 15) were studied.
Third, we did not measure urinary prostaglandin excretion and
phosphaturic hormone fibroblast growth factor level [15].
In conclusion, this case–control study demonstrates the
existence of a tendency towards elevated circulating PTH
levels and renal phosphate wasting in Bartter patients with
normal GFR. A multicenter study with a large number of
patients and the determination of prostaglandinuria,
reninemia, fibroblast growth factor 23, and 1,25-
dihydroxyvitamin D should be helpful in establishing the
mechanisms underlying these biochemical abnormalities.
Conflict of interest None.
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